Do NOACs Result in Any Benefit in TAVR?

Courtesy of Dr. Carlos Fava.

The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15% according to different reports and, so far, no one has analyzed in depth whether new oral anticoagulant agents (non-vitamin K oral anticoagulants [NOACs]) result in superior benefit compared with classic vitamin K antagonists (VKAs).

This study analyzed 962 patients. Among them, 326 received NOACs (33.9%) and 636 received VKAs (66.1%).

The primary endpoint at 12 months was a composite of all-cause mortality, acute myocardial infarction, and stroke.

Groups were similar: the mean age was 81 years, 52% of patients were women, the Society of Thoracic Surgeons (STS) score was 4.5%, and the CHA2DS2 VASC Score ≥2, 95.2%. Balloon-expandable valves were the most used valves.


Read also: Must Post MI Patients Use B Blockers for Life?


At 30 days, there were no differences in mortality, major bleeding, or life-threatening bleeding, but NOAC patients had higher rates of non-disabling stroke compared with VKA patients (1.2% vs. 0%; p < 0.001).

At 1 year, the primary endpoint was higher for NOAC patients (20.9% vs. 14.4%; hazard ratio [HR] 1.47; 95% confidence interval [CI]: 1.06 to 2.04; p 0 = 0.018); there were no differences as regards mortality, acute myocardial infarction, or bleeding. The rates of non-disabling stroke were higher for NOAC patients (1.6% vs. 0.3%; HR: 5.00; 95% CI: 0.97 to 25.81; p = 0.054).

Conclusion

Chronic use of NOACs and VKAs among patients in need of oral anticoagulation after TAVR resulted in comparable bleeding risk at 1 year. NOACs resulted in a higher ischemic event rate, something that should be evaluated in large randomized trials.

Courtesy of Dr. Carlos Fava.

Original Title: Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement.

Reference: David Jochheim, et al. JACC cardiovasc Interven. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...